These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8844336)

  • 1. Antibodies to interferon in patients undergoing IFN therapy: an update.
    Antonelli G
    J Biol Regul Homeost Agents; 1995; 9(4):123-31. PubMed ID: 8844336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of antibodies to interferon beta in patients: technical and biological aspects.
    Antonelli G; Dianzani F
    Eur Cytokine Netw; 1999 Sep; 10(3):413-22. PubMed ID: 10477398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
    Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
    Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural autoantibodies to interferons.
    Meager A
    J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S51-3. PubMed ID: 9241617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assays for antibodies to human interferon-alpha: the need for standardization.
    Schellekens H; Ryff JC; van der Meide PH
    J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S5-8. PubMed ID: 9241609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon.
    Thurmond LM; Brand CM; Leventhal BG; Finter NB; Johnston JM
    J Lab Clin Med; 1991 Sep; 118(3):232-40. PubMed ID: 1919296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha.
    Kansu A; Kuloğlu Z; Demirçeken F; Girgin N
    Turk J Gastroenterol; 2004 Dec; 15(4):213-8. PubMed ID: 16249973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the practical significance of antibodies to interferons?
    Dianzani F; Antonelli G
    BioDrugs; 1998 Mar; 9(3):187-95. PubMed ID: 18020559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha.
    Jorns C; Holzinger D; Thimme R; Spangenberg HC; Weidmann M; Rasenack J; Blum HE; Haller O; Kochs G
    J Med Virol; 2006 Jan; 78(1):74-82. PubMed ID: 16299717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine therapy for hematological malignancies.
    Ezaki K; Tsuzuki M
    Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():182-94. PubMed ID: 9210900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The influence of interferon alpha neutralizing antibodies on the therapeutic effectiveness in patients with chronic viral hepatitis].
    Tong F; Tang Y; Bai J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):345-7. PubMed ID: 12759973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.
    Eriksen KW; Søndergaard H; Woetmann A; Krejsgaard T; Skak K; Geisler C; Wasik MA; Odum N
    Mol Immunol; 2009 Feb; 46(5):812-20. PubMed ID: 18947877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo development of antibody to interferons: an update to 1996.
    Antonelli G
    J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S39-46. PubMed ID: 9241615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunization against interferon in man].
    Pozzetto B; Mogensen KE
    Pathol Biol (Paris); 1986 Dec; 34(10):1097-103. PubMed ID: 2434903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.
    Bello-Rivero I; Cervantes M; Torres Y; Ferrero J; Rodríguez E; Pérez J; García I; Díaz G; López-Saura P
    J Autoimmun; 2004 Aug; 23(1):63-73. PubMed ID: 15236754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A scFv antibody fragment as a therapeutic candidate to neutralize a broad diversity of human IFN-alpha subtypes.
    Depetris M; Casalis P; Kratje R; Etcheverrigaray M; Oggero M
    J Immunol Methods; 2008 May; 334(1-2):104-13. PubMed ID: 18394641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects.
    Kontsek P; Liptáková H; Kontseková E
    Acta Virol; 1999 Feb; 43(1):63-70. PubMed ID: 10672347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.